Comparative Pharmacology
Head-to-head clinical analysis: ADHANSIA XR versus DYANAVEL XR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADHANSIA XR versus DYANAVEL XR 10.
ADHANSIA XR vs DYANAVEL XR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
None Documented
None Documented
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Category C
Category C
CNS Stimulant
CNS Stimulant